[Metabolic syndrome and plasma fibrinogen in type 2 diabetic patients].

Metabolic syndrome is a group of factors which increase the risk for development of diabetes, cardiovascular diseases and includes insulin resistance, abdominal adiposity, hyperlipidemia, hypertension and other disorders. Changes in prothrombotic and proinflammatory markers have been observed. Aim of this study was to asses the concentration of fibrinogen and other humoral markers of metabolic syndrome in type 2 diabetic patients. 77 patients both sexes, age 46-83 years have been included. Based on ATP III criteria patients were divided in two groups. Group I - diabetic patients with metabolic syndrome and Group II - diabetic patients without metabolic syndrome. Each group was divided in two subgroups, males and females. The plasma concentration of fibrinogen and humoral markers of metabolic syndrome (triglycerides, cholesterol and glucose) have been evaluated. There were 49.4% patients out of total who met the criteria for metabolic syndrome. Patients in Group I weight in average more then the patients in Group II. Average systolic and diastolic blood pressure values were in all groups and subgroups higher than recommended. Humoral markers of metabolic syndrome were significantly higher (p<0.05) in Group I (triglycerides 2.7+/-0,2 mmol/L, total cholesterol 6.0+/-0.2 mmol/L) compared to Group II (triglycerides up to 1,7 mmol/L, total cholesterol in serum up to 5,2 mmol/L ). Concentration of glucose in both groups was significantly higher compared to referral values. Average plasma fibrinogen concentration was 4.0+/-0.1 g/Lwithout significant differences between Group I and II. Females from Group I had significantly higher fibrinogen concentration (p=0.003) then the males from the same group (females 4.4+/-0.2 g/L vs. males 3.7+/-0.1 g/L). There was no difference in fibrinogen concentration between female and male patients in Group II. Fibrinogen plasma concentration is elevated in all type 2 diabetic patients without significant differences between subjects with or without metabolic syndrome.